4 Oct 2019 07:00
Sensyne Health Announces Related Party Transactions
Oxford, UK; 04 October 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, announces that in December 2018 Lord Drayson, CEO, and Lorrie Headley, CFO, were awarded and paid post IPO bonuses of £850,000 and £200,000, respectively (the "Payments").
While the Company received a preliminary view from Peel Hunt LLP ("Peel Hunt"), the Company's nominated adviser and broker, as to a likely unfavourable market reaction to the proposed Payments, the Company did not discuss the proposals further with Peel Hunt prior to making the Payments. Peel Hunt was recently made aware, during the preparation of the Company's annual report, that the Payments had been made in December 2018 and has advised the Company that they constituted related party transactions that required notification at the time under Rule 13 of the AIM Rules for Companies. The Directors (other than Lord Drayson and Lorrie Headley) considered the Payments to be appropriate and remain of that view. Peel Hunt cannot advise as to whether the Payments were fair and reasonable.
The Company intends to consult with its major institutional shareholders on the Payments and its remuneration policy following the publication of its annual report on 7 October 2019.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson, Chief Executive Officer | |
Lorimer Headley, Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Broker) | + 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
Consilium Strategic Communications | +44 20 3709 5700 |
Mary-Jane Elliott | |
Sukaina Virji | |
Melissa Gardiner | |
sensynehealth@consilium-comms.com |
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com